Project Grant K43TW011942
- This $478,503 Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health program (CFDA 93.113) supports research to investigate the impact of prenatal exposure to per- and polyfluoroalkyl substances (PFAS) on the development of non-alcoholic fatty liver disease (NAFLD) in children. The award will leverage the existing GUSTO mother-child cohort in Singapore to conduct comprehensive assessments, including proton magnetic resonance...
- This Project Grant award from the National Institute of Environmental Health Sciences (NIEHS), under the Environmental Health (CFDA 93.113) federal grant program, provides $695,853 to the Arkansas Children's Research Institute (ACRI) from December 1, 2024 to November 30, 2029. The project will investigate the impact of prenatal and postnatal exposure to per- and polyfluoroalkyl substances (PFAS) on children's development, examining the role of placental function and the potential protective...
- This Project Grant award of $132,651.00 from the National Institute of Environmental Health Sciences (NIEHS), under the Environmental Health Federal Grant Program (CFDA 93.113), will support research on the impacts of prenatal and early-life air pollution exposure on pubertal development in girls and boys. The key products and services to be delivered through this 5-year grant include: 1) Investigating associations between air pollution exposure before conception, during pregnancy, and in...
- This Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health federal grant program (CFDA 93.113) provides $847,498 to New York University Grossman School of Medicine and Erasmus University Medical Center to evaluate how organophosphate pesticides, glyphosate, phthalates and bisphenols contribute to renal risks in childhood and adolescence. The key objectives are to investigate how intrauterine inflammatory processes and...
- This federal Project Grant award from the National Institute of Environmental Health Sciences (NIEHS), under the Environmental Health (CFDA 93.113) program, provides $121,057 to Trustees of Boston University (doing business as Boston University Medical Campus) to conduct a prospective study investigating associations between per- and polyfluoroalkyl substance (PFAS) mixtures and pregnancy outcomes among Black women. The research aims to: 1) evaluate the association of a PFAS mixture with adverse...
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research), will fund a $431,377 investigation by Yale University to examine the relationship between prenatal exposure to per- and polyfluoroalkyl substances (PFAS) and the risk of glioma, a common and deadly type of childhood brain cancer, in young children aged 0-5 years. The study will utilize both targeted and non-targeted approaches to analyze PFAS exposure and its...
- This $899,426 Project Grant from the Fogarty International Center (CFDA 93.989 - International Research and Research Training) will support Dr. Cameron Gaskill at the University of California, Davis (UC Davis) to establish an independent global health research program addressing liver cancer in sub-Saharan Africa. The key products and services to be delivered under this 5-year award include: Piloting a national liver cancer treatment outcomes registry in Tanzania to assess the impact of location...
- This federal Project Grant award of $165,883 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports a research project led by Dr. Xinyuan (Cindy) Zhang at Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to improve early detection, causal inference, and lifestyle-based prevention for hepatocellular carcinoma (HCC). The key objectives of this 2-year research project are to: Use computational biology and system biology techniques to...
- The National Institute of Environmental Health Sciences (NIEHS), under the Environmental Health Federal Grant Program (CFDA 93.113), awarded a $2,472,661 Project Grant to the Texas A&M University System Health Science Center (TAMU HSC) to investigate the effects of phthalate exposure on epigenetic regulation of metabolic pathways and the development of metabolic diseases. The 4-year project, commencing on September 15, 2025, aims to elucidate the mechanisms by which phthalates, a group of...
- This R21 Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program provides $433,950 to the University of California, Davis to study the impact of wildfire smoke exposure on lung injury and disease in pediatric populations. The key objectives are to: 1) Define the contribution of age on the toxicity of wood smoke particles in respiratory and alveolar epithelium, 2) Investigate the effect of early life wood...
EARLY LIFE AFLATOXIN B1 EXPOSURE AND EPIGENETIC PROGRAMMING IN NIGERIAN NEWBORNS - PROJECT SUMMARY AFLATOXIN B1 (AFB1) IS A MAJOR CAUSE OF HEPATOCELLULAR CARCINOMA (HCC) IN SUB SAHARAN AFRICA, WHERE AFLATOXIN CONTAMINATION IS COMMON. IN THESE AREAS, EXPOSURE TO AFB1 STARTS EARLY IN LIFE THROUGH MATERNAL ROUTES DURING PREGNANCY. POPULATIONS IN THESE COUNTRIES EXPERIENCE EARLY ONSET OF HCC, AND IN UTERO AFB1 EXPOSURE MAY BE A CONTRIBUTING FACTOR TO THE ONSET OF THE DISEASE. EXPOSURES TO NUTRIENTS, TOXIC CHEMICALS AND BIOLOGICAL AGENTS DURING GESTATION AND EARLY CHILDHOOD PLAY A CRITICAL ROLE IN DETERMINING SUSCEPTIBILITY TO DISEASES LATER IN LIFE. THE MECHANISM OF EARLY ONSET OF CARCINOGENESIS MAY INCLUDE EPIGENETIC CHANGES IN TUMOR SUPPRESSOR GENES (TSGS). OUR PREVIOUS RODENT STUDY SHOWED THAT IN UTERO AFB1 EXPOSURE CAN ALTER DNA METHYLATION OF TSGS. IT IS NECESSARY TO INVESTIGATE THE IMPACT OF IN UTERO AFB1 EXPOSURE ON METHYLATION AND EXPRESSION OF TSGS IN HUMANS. THE OVERALL HYPOTHESIS IS THAT IN UTERO AFB1 EXPOSURE WILL DIFFERENTIALLY METHYLATE TSGS, AND THIS METHYLATION WILL INVERSELY CORRELATE WITH THE EXPRESSION OF THE TSGS. THE OVERALL OBJECTIVE OF THIS PROJECT IS TO ESTABLISH A PRE-BIRTH COHORT AND STUDY THE ASSOCIATION BETWEEN IN UTERO EXPOSURE TO AFB1 AND DNA METHYLATION CHANGES IN TSGS OF NEWBORNS IN NIGERIA. TO ACHIEVE THIS, WE WILL RECRUIT PREGNANT WOMEN IN THE FIRST TRIMESTER FROM TWO NIGERIAN HOSPITALS SERVING A RURAL AND AN URBAN AREA. WE HYPOTHESIZE THAT NIGERIAN WOMEN WILL HAVE A RANGE OF AFB1 EXPOSURE LEVELS DETECTABLE IN PLASMA. WE HYPOTHESIZE THAT IN UTERO AFB1 EXPOSURE WILL BE ASSOCIATED WITH DIFFERENTIAL METHYLATION AND EXPRESSION OF TSGS IN CORD BLOOD SAMPLES. THE SPECIFIC AIMS OF THIS PROJECT ARE TO 1) DETERMINE THE LEVELS OF AFB1 IN THE PLASMA OF PREGNANT WOMEN, USING HPLC, COLLECTED DURING THE FIRST AND THIRD TRIMESTERS OF PREGNANCY, AND NEWBORNS (CORD BLOOD), 2) ASSESS THE DNA METHYLATION OF TSGS IN THE CORD BLOOD VIA PYROSEQUENCING AND TO DETERMINE IF AFB1 CONCENTRATION IS ASSOCIATED WITH THE LEVELS OF DNA METHYLATION, 3) DETERMINE THE EXPRESSION OF TSGS IN THE CORD BLOOD USING REAL-TIME QUANTITATIVE PCR AND DETERMINE IF GENE EXPRESSION IS INVERSELY CORRELATED WITH METHYLATION CHANGES IN THE TSGS. THE FINDINGS OF THIS STUDY WILL PROVIDE DATA ON AFB1 EXPOSURE AMONG PREGNANT WOMEN IN NIGERIA AND ITS SUBSEQUENT EFFECT ON THE EPIGENOME OF NEWBORNS. THIS DATA WILL PROVIDE DIRECTION FOR FUTURE RESEARCH DEVELOPING EPIGENETIC BIOMARKERS OF AFB1 EXPOSURE AS WELL AS INVESTIGATING EPIGENETIC MECHANISMS ASSOCIATED WITH PRENATAL EXPOSURE TO AFB1 AND THE RISK OF DEVELOPING LIVER CANCER IN AFRICA. THIS RESEARCH DIRECTION MAY PROVIDE INSIGHT INTO REDUCING THE INCIDENCE OF THIS CANCER IN SUB-SAHARAN AFRICA, ESPECIALLY IN COUNTRIES SUCH AS NIGERIA, WHERE AFB1 EXPOSURE IS HIGHLY PREVALENT. THROUGH THIS RESEARCH, THE PI WILL BECOME A LEADER IN ENVIRONMENTAL EPIGENETICS, STUDYING HOW EARLY-LIFE EXPOSURE TO ENVIRONMENTAL CONTAMINANTS OF PUBLIC HEALTH CONCERNS IN AFRICA CONTRIBUTES TO THE DEVELOPMENT OF NON- COMMUNICABLE DISEASES LATER IN LIFE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $46.3k | 7/14/25 | ||
| Not listed | $40.0k | 7/2/24 | ||
| Not listed | $46.8k | 6/26/23 | ||
| Not listed | $40.0k | 6/26/23 | ||
| Not listed | $40.0k | 9/16/22 |